Supportive Care in Cancer

, Volume 16, Issue 7, pp 847–852 | Cite as

Prophylactic anti-coagulation in cancer palliative care: a prospective randomised study

  • Catherine Weber
  • Thierry Merminod
  • François R. Herrmann
  • Gilbert B. Zulian
Original Article

Abstract

Goals

The objective of this study was to determine utility of prophylactic anti-coagulation in cancer patients hospitalised for palliative care in a specialised centre.

Materials and methods

Prospective 1:1 open randomised study was designed. Twenty patients aged 55 to 88 years with advanced cancer and an estimated life expectancy of less than 6 months were assigned to either receive treatment with 2,850/3,800 U (<70/>70 kg) of daily subcutaneous nadroparin or no treatment. Suspicion of venous thrombo-embolism (deep vein thrombosis and pulmonary embolism) was confirmed by echo-Doppler examination of the lower limbs and/or by spiral computed tomography scan of the lungs. Bleeding episodes were recorded. Platelet count was measured on days 7 and 14. Survival time from study entry was determined.

Main results

One venous thrombo-embolism and one major bleeding occurred in the group receiving nadroparin, whereas two minor bleedings occurred in the control group. At 3 months, nine of ten participants had died in the control group vs five of ten in the group receiving nadroparin (P = 0.141). Five participants could be discharged home (P = 0.141).

Conclusions

Decision to administer prophylactic nadroparin in hospitalised cancer patients under palliative care remains a challenge. Better mobility score at admission and the likelihood to be discharged home may be useful for practical purposes. The observation of a potential influence of prophylactic nadroparin on survival deserves further studies.

Keywords

Anti-coagulation Cancer Palliative care Thrombosis Bleeding 

References

  1. 1.
    Agrawal M, Danis M (2002) End-of-life care for terminally ill participants in clinical research. J Palliat Med 5:729–737PubMedCrossRefGoogle Scholar
  2. 2.
    Baron JA, Gridley G, Weiderpass E, Nyren O, Linet M (1998) Venous thromboembolism and cancer. Lancet 351:1077–1080PubMedCrossRefGoogle Scholar
  3. 3.
    Bruera E, Neumann CM (1998) Management of specific symptom complexes in patients receiving palliative care. Can Med Assoc J 158:1717–1726Google Scholar
  4. 4.
    Bruera E, Miller L, McCallion J, Macmillan J et al (1992) Cognitive failure in patients with terminal cancer: a prospective study. J Pain Symptom Manage 7:192–195PubMedCrossRefGoogle Scholar
  5. 5.
    Casarett DJ, Karlawish JHT (2000) Are special ethical guidelines needed for palliative care research? J Pain Symptom Manage 20:130–139PubMedCrossRefGoogle Scholar
  6. 6.
    Deitcher SR, Gomes MP (2004) The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review. Cancer 101:439–449PubMedCrossRefGoogle Scholar
  7. 7.
    Federal Office of Statistics (Switzerland). http://www.bfs.admin.ch/
  8. 8.
    Folstein MF, Folstein SE, Mc Hugh PR (1975) Mini-Mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198PubMedCrossRefGoogle Scholar
  9. 9.
    Goodnough LT, Saito H, Manni A, Jones PK, Pearson OH (1984) Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients. Cancer 54:1264–1268PubMedCrossRefGoogle Scholar
  10. 10.
    Gouin-Thibaut I, Samama MM (2000) Venous thrombosis and cancer. Ann Biol Clin (Paris) 58:675–682Google Scholar
  11. 11.
    Hawryluck L (2004) People at the end of life are a vulnerable research population. Clin Oncol 16:225–226CrossRefGoogle Scholar
  12. 12.
    Jacobs LG (2003) Prophylactic anticoagulation for venous thromboembolic disease in geriatric patients. J Am Geriatr Soc 51:1472–1478PubMedCrossRefGoogle Scholar
  13. 13.
    Jilma B, Kamath S, Lip GYH (2003) Antithrombotic therapy in special circumstances. II-in children, thrombophilia, and miscellanaous conditions. Br Med J 326:93–96CrossRefGoogle Scholar
  14. 14.
    Johnson MJ, Sherry K (1997) How do palliative physicians manage venous thromboembolism? Palliat Med 11:462–468PubMedCrossRefGoogle Scholar
  15. 15.
    Kakkar AK, Levine MN, Kadziola Z et al (2004) Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: The Fragmin Advanced malignancy Outcome Study (FAMOUS). J Clin Oncol 22:1944–1948PubMedCrossRefGoogle Scholar
  16. 16.
    Keith RA, Granger CV, Hamilton BB, Sherwin FS (1987) The functional independence measure: a new tool for rehabilitation. Adv Clin Rehabil 1:6–18PubMedGoogle Scholar
  17. 17.
    Klerk CPW, Smorenburg SM, Otten HM et al (2005) The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 23:2130–2135PubMedCrossRefGoogle Scholar
  18. 18.
    Koedoot CG, de Haan RJ, Stiggelbout AM et al (2003) Palliative chemotherapy or best supportive care? A prospective study explaining patients’ preference and choice. Br J Cancer 89:2219–2226PubMedCrossRefGoogle Scholar
  19. 19.
    Lee AYY (2003) Epidemiology and management of venous thromboembolism in patients with cancer. Thromb Res 110:167–172PubMedCrossRefGoogle Scholar
  20. 20.
    Leizorovicz A, Cohen AT, Turpie AGG et al (2004) Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 110:874–879PubMedCrossRefGoogle Scholar
  21. 21.
    Mazzocato C, Sweeney C, Bruera E (2001) Clinical research in palliative care: choice of trial design. Palliat Med 15:261–264PubMedCrossRefGoogle Scholar
  22. 22.
    Merminod T, Zulian GB (2007) Venous thromboembolism in cancer patients under palliative care: retrospective study with lessons to the future. Supportive Palliative Cancer Care J (in press)Google Scholar
  23. 23.
    Pautex S, Moynier K, Weber C, Zulian GB (2002) L’évaluation des symptômes en oncologie palliative. Méd Hyg 60:1313–1317Google Scholar
  24. 24.
    Samama MM, Cohen AT, Darmon JY et al (1999) A comparaison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. New Eng J Med 341:793–800PubMedCrossRefGoogle Scholar
  25. 25.
    Saphner T, Tormey DC, Gray R (1991) Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 9:286–294PubMedGoogle Scholar
  26. 26.
    Trousseau A (1865) Phlegmasia Alba Dolens. Clinique médicale de l’Hôtel Dieu de Paris, vol 3. The New Sydenham Society, London, p 94Google Scholar
  27. 27.
    Wilson CB, Lambert HE, Scott RD (1987) Subclavian and axillary vein thrombosis following radiotherapy for carcinoma of the breast. Clin Radiol 38:95–96PubMedCrossRefGoogle Scholar
  28. 28.
  29. 29.
    Yancik R (2005) Population aging and cancer: a cross-national concern. Cancer 11:437–441CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Catherine Weber
    • 1
  • Thierry Merminod
    • 1
  • François R. Herrmann
    • 1
  • Gilbert B. Zulian
    • 1
  1. 1.Department of Rehabilitation and Geriatrics, Service of Palliative Medicine CescoUniversity Hospitals of GenevaCollonge-BelleriveSwitzerland

Personalised recommendations